Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021

Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands

Zsὁfia Iglὁi, Jans Velzing, Janko van Beek, David van de Vijver, Georgina Aron, Roel Ensing, Kimberley Benschop, Wanda Han, Timo Boelsums, Marion Koopmans, Corine Geurtsvankessel, and Richard Molenkamp

Author affiliations: Erasmus MC, Rotterdam, the Netherlands (Z. Igloi, J. Velzing, J. van Beek, D. van de Vijver, G. Aron, M. Koopmans, C. Geurtsvankessel, R. Molenkamp); Public Health Service Rotterdam-Rijnmond, Rotterdam (R. Ensing, T. Boelsums); National Public Health Institute (RIVM), Bilthoven, the Netherlands (K. Benschop, W. Han)

Main Article

Table 4

Results of rapid antigen detection test for severe acute respiratory syndrome coronavirus 2, the Netherlands*

Time to result Result, no. (%)
+/− + ++
5 min NA 1 (7) 8 (24) 108 (95) 117
10 min NA 3 (20) 12 (36) 4 (4) 19
15 min
11 (73)
13 (39)
2 (1)
Total tests 808 15 33 114 970

*Results of the Ag RDT were recorded at 3 time points: 5 min, 10 min, and the manufacturer-recommended 15 min. If result between first and last readout did not change, the first was registered as final result. Ag RDT, rapid antigen detection test; NA, not applicable; −, negative; +/− weak positive; +, positive; ++, strong positive.

Main Article

Page created: March 16, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.